IP Chemotherapy Ovarian — SCE Medical Oncology MCQ
Instant feedback + full explanation. One question, done properly.
Educational content. Not a substitute for clinical judgement or local policy.
Reveal the answer and explanation
Correct answer: C — Intraperitoneal cisplatin-paclitaxel improved overall survival
GOG 172 (Armstrong et al NEJM 2006) demonstrated a striking 16-month OS improvement with IP chemotherapy in optimally debulked stage III EOC. However, IP toxicity (abdominal pain, catheter complications, renal toxicity) caused >50% of patients to not complete all planned IP cycles. This led to modified IP regimens and the development of HIPEC approaches. GOG 252 did not replicate the IP benefit with modified regimens. Current practice: IP chemotherapy is available at specialist centres but is not universally adopted. HIPEC (OVHIPEC-1) represents an evolution of the IP concept.
Reference: https://www.nice.org.uk/guidance/conditions-and-diseases/cancer